Huntington's disease treatment aims to manage symptoms and improve quality of life. Currently, there is no cure for this neurodegenerative disorder, which is characterized by involuntary movements, emotional problems, and loss of intellectual abilities. Drugs like tetrabenazine help control movement problems by reducing levels of a neurotransmitter called dopamine in the brain. Antidepressants and antipsychotics may help manage mood and behavioral symptoms. Physiotherapy and occupational therapy helps improve mobility and daily activities. Gene silencing techniques being researched aim to potentially slow progression by blocking production of the abnormal protein associated with Huntington's disease.
The Global Huntington's Disease Treatment Market is estimated to be valued at US$ 0.55 Mn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Huntington's Disease Treatment are Unilever Plc., Coty Inc., Johnson & Johnson Inc., Proctor & Gamble Co., L€TMOreal S.A., Revlon Inc., Kao Corporation, Avon Products Inc., Beiersdorf AG., Colgate Palmolive Company, Natura & co., and Estee Lauder Inc. The key players are extensively focused on development and commercialization of therapeutics for the disease. For instance, in June 2021, UniQure N.V. announced positive topline results from its ongoing phase I/II clinical trial of AMT-130 in early manifest Huntington's disease patients dosed at 4 mg.
The key opportunities in the Huntington's Disease Treatment market include emergence of pipeline therapies such as gene silencing drugs and rise in investment by pharmaceutical companies to develop novel disease modifying therapeutics. Further, growing awareness regarding availability of treatment options and support groups is also expected to contribute to the market growth.
Globally, North America dominated the Huntington's Disease Treatment market in 2024 owing to increasing research collaborations between biotechnology and pharmaceutical companies in the region. However, Asia Pacific is expected to witness highest growth rate over the forecast period owing to rising healthcare expenditure, presence of less stringent regulations for clinical trials, and surge in healthcare awareness in major Asian countries including China and India.
Market Drivers
Increased research funding for finding advanced treatment and rising awareness about the disease are the major factors driving the growth Of Huntington's Disease Treatment Market Demand . According to the Huntington's Disease Society of America, around 30,000 people in the U.S. may have Huntington's disease. Rising prevalence of the disease along with advent of targeted therapies will contribute to the market growth during the forecast period.
Market Restraints
High costs associated with drug development and treatment procedures and lack of biomarkers to predict efficacy of treatment options are major challenges restraining the growth of Huntington's disease treatment market. Further, lack of approved drugs specifically targeting the disease is another factor hampering the market growth. Long duration required for clinical development and complex gene silencing techniques also pose drawbacks for industry players.
Segment Analysis
The Huntington's disease treatment market is segmented into drug class and distribution channel. The drug class segment dominates the market consisting of antipsychotics, antidepressants, and anti-anxiety medications. Antipsychotics medication is the most dominating sub segment as it helps reduce abnormal movements, tics, and other physical symptoms of Huntington's disease.
The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominate the segment as patients are giving treatment and medicines under supervision of doctors in hospitals.
Global Analysis
North America has the largest share in the Huntington's disease treatment market due to increasing prevalence of Huntington's disease and growing healthcare expenditure. The rise in healthcare awareness and presence of developed healthcare infrastructure also contributes to the dominating share of the region. Asia Pacific is expected to witness the fastest growth during the forecast period owing to rising patient awareness levels and improving healthcare facilities.
Explore more information on this topic, Please visit-
https://www.insightprobing.com/huntingtons-disease-treatment-market-growth-and-trnds-analysis-share-size-demand-forecast/
Comments
0 comment